Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Recommendation of “Hold” from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been given an average recommendation of “Hold” by the eight brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.75.

A number of brokerages recently issued reports on HOWL. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. HC Wainwright dropped their price target on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Bank of America lowered their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday.

Insider Activity

In related news, Director Luke Evnin sold 58,980 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $0.57, for a total value of $33,618.60. Following the sale, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. The trade was a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 6,019,118 shares of company stock worth $6,524,766. 23.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in HOWL. Susquehanna International Group LLP raised its stake in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares during the period. Quadrature Capital Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the period. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the second quarter worth $48,000. Finally, Bridgeway Capital Management LLC lifted its stake in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.70 on Friday. The business’s 50 day moving average price is $0.79 and its 200 day moving average price is $1.21. The company has a market cap of $33.82 million, a price-to-earnings ratio of -0.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, research analysts predict that Werewolf Therapeutics will post -1.56 EPS for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.